1462-86-8

Basic information

• Product Name: 3-Amino-2-pyridinecarboxylic acid
• Synonyms: RARECHEM AQ NN 0176;3-amino-2-pyridinecarboxylicaci;3-AMINO-2-PYRIDINECARBOXYLIC ACID;3-AMINO-PYRIDINE-2-CARBOXYLIC ACID;3-AMINOPICOLINIC ACID;AKOS 92172;IFLAB-BB F2113-0045;H-3APC2-OH
• CAS NO: 1462-86-8
• Molecular Formula: C₆H₆N₂O₂
• Molecular Weight: 138.12
• EINECS: 215-971-8
• Product Categories: AMINOACID;Pyridine;pharmacetical;Pyridine series;Carboxylic Acids;Pyridines;Organic acids;Aromatics Compounds;Aromatics;Carboxylic Acids;Amines;Heterocycles;Heterocycle-Pyridine series
• Mol File: 1462-86-8.mol
• Article Data: 6

Chemical Properties

• Melting Point: 218-220
• Boiling Point: 386.6 °C at 760 mmHg
• Flash Point: 187.6 °C
• Appearance: Yellow to pale brown/Solid
• Density: 1.417 g/cm³
• Vapor Pressure: 1.14E-06mmHg at 25°C
• Storage Temp.: -20°C Freezer
• Solubility: Soluble in acetone, ethanol and methanol.
• PKA: 1.32±0.50(Predicted)
• CAS DataBase Reference: 3-Amino-2-pyridinecarboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Amino-2-pyridinecarboxylic acid(1462-86-8)
• EPA Substance Registry System: 3-Amino-2-pyridinecarboxylic acid(1462-86-8)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-37-60
• RTECS: US5175000
• HazardClass: IRRITANT
• Hazardous Substances Data: 1462-86-8(Hazardous Substances Data)

Usage

Description

3-Amino-2-pyridinecarboxylic acid is an organic compound characterized by its green or brown crystalline structure. It is a versatile synthetic intermediate with significant applications in various industries, particularly in the synthesis of materials and pharmaceuticals.

Uses

Used in Pharmaceutical Industry:
3-Amino-2-pyridinecarboxylic acid is used as a crucial intermediate for the synthesis of various pharmaceutical compounds. Its role in the development of new drugs is essential due to its unique chemical properties and reactivity.
Used in Synthesis Material:
3-Amino-2-pyridinecarboxylic acid is also employed as an important intermediate in the synthesis of materials, where its chemical structure contributes to the creation of novel compounds with specific properties.
Used in Anticancer Applications:
3-Aminopicolinic Acid, a derivative of 3-Amino-2-pyridinecarboxylic acid, is used in the preparation of piperidinyl-methyl-purinamines. These compounds act as NSD2 inhibitors and are recognized for their anti-cancer properties, making them valuable in the development of new cancer treatments.

InChI:InChI=1/C6H6N2O2/c7-4-2-1-3-8-5(4)6(9)10/h1-3H,7H2,(H,9,10)/p-1

Upstream product

• 4664-00-0 2,3-pyridinedicarboximide 
• 4663-94-9 pyridine-2,3-dicarboxamide 
• 89-00-9 Pyridine-2,3-dicarboxylic acid 
• 699-98-9 Pyridine-2,3-dicarboxylic anhydride 
• 59290-85-6 3-nitropyridine-2-carboxylic acid 

Downstream Products

• 27507-15-9 ethyl 3-aminopyridine-2-carboxylate 
• 110967-13-0 2-amino-3H-pyrido[3,2-d]pyrimidin-4-one 
• 37538-67-3 pyrido[3,2-d]-pyrimidin-4(3H)-one 
• 53636-38-7 3-phenylsulfanyl-pyridine-2-carboxylic acid 
• 856835-78-4 3-(4-nitro-phenylsulfanyl)-pyridine-2-carboxylic acid 
• 37538-68-4 pyrido<3,2-d>pyrimidine-2,4(1H,3H)-dione 
• 462-08-8 pyridin-3-ylamine 
• 57266-69-0 3-chloropyridine-2-carboxylic acid 
• 73841-32-4 3-iodopyridine-2-carboxylic acid 
• 3303-17-1 2-methyl-pyrido[3,2-d][1,3]oxazin-4-one 
• 39564-88-0 3-(4-chloro-phenyl)-pyrido[3,2-d]thiazolo[3,2-a]pyrimidin-5-one 
• 107805-64-1 5,6,7,8-Tetrahydro-1,8a,10-triaza-anthracen-9-one 
• 25379-86-6 3-Phenyl-1,2,3,4-tetrahydropyrido<3,2-d>pyrimidin-4-one-2-thione 
• 110606-40-1 3-benzyloxycarbonylaminopicolinic acid 

Relevant articles and documents

BICYCLIC PYRIMIDIN-4-(3H)-ONES AND ANALOGUES AND DERIVATIVES THEREOF WHICH MODULATE THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1)

Compounds of formula (I); which are useful as therapeutic compounds, particularly in the treatment of pain and other conditions ameliorated by the modulation of the function of the vanilloid-1 receptor (VR1).

Synthesis and SAR of 5-, 6-, 7- and 8-aza analogues of 3-aryl-4-hydroxyquinolin-2(1H)-one as NMDA/glycine site antagonists

A series of 5-, 6-, 7- and 8-aza analogues of 3-aryl-4-hydroxyquinolin-2(1H)-one was synthesized and assayed as NMDA/glycine receptor antagonists. The in vitro potency of these antagonists was determined by displacement of the glycine site radioligand [3H]5,7-dicholorokynurenic acid ([3H]DCKA) in rat brain cortical membranes. Selected compounds were also tested for functional antagonism using electrophysiological assays in Xenopus oocytes expressing cloned NMDA receptor (NR) 1A/2C subunits. Among the 5-, 6-, 7-, and 8-aza-3-aryl-4-hydroxyquinoline-2(1H)-ones investigated, 5-aza-7-chloro-4-hydroxy-3-(3-phenoxyphenyl)quinolin-2-(1H)-one (13i) is the most potent antagonist, having an IC50 value of 110 nM in [3H]DCKA binding and a Kb of 11 nM in the electrophysiology assay. Compound 13i is also an active anticonvulsant when administered systemically in the mouse maximum electroshock-induced seizure test (ED50 = 2.3 mg/kg, IP).

Synthesis and pharmacological activity of triazole derivatives inhibiting eosinophilia

In order to develop novel antiasthmatic agents based on a new mechanism of action, a series of 3-substituted 5-amino-1- [(methylamino)(thiocarbonyl)]-1H-1,2,4-triazole derivatives were synthesized and evaluated in a model in which eosinophilia was induced in the airway through intravenous (iv) injection of Sephadex particles on days 0, 2, and 5. After screening of several hundred derivatives, we finally identified the highly potent eosinophilia inhibitor 5-amino-3-(4-chlorophenyl)-1- [(methylamino)(thiocarbonyl)]-1H-triazole (23c, GCC-AP0341), which had ID50 values of 0.3 and 0.07 mg/kg when administered orally (os) and intraperitoneally (ip), respectively. This compound showed complete inhibition of the hypersensitivity induced by ascaris inhalation at an ip dose of 1 mg/kg as well as low toxicity, with an LD50 value of >2.0 g/kg in mice. Extensive study of its mechanism of action revealed that 23c inhibited eosinophil survival induced by interleukin-5 (IL-5), but had little or no effect on leukotriene D4 (LTD4) or platelet-activating factor (PAF)- induced responses. Taken together, these results suggest 23c as a novel candidate for the treatment of chronic asthma. Further studies are now underway.